News

450 patients with symptomatic peripheral arterial obstructive disease (PAOD) and intermittent claudication (leg pain during walking) have been recruited. The phase II trial was designed with an independent

Ventavis (iloprost) was recently approved by the FDA for the treatment of pulmonary arterial hypertension (PAH) in patients with New York Heart Association class III or IV symptoms.

MCAA (monochloroacetic acid) is used in the manufacture of detergents, adhesives, textile auxiliaries and thickeners used in foods, pharmaceuticals and cosmetics. The fines are part of the commission’s

Sention will develop a family of Merck compounds known as mGluR5 antagonists as potential treatments for fragile X, the most commonly inherited form of mental retardation. The agreement

After reviewing the Exanta (ximelagatran) regulatory submission made in December 2003, the French Regulatory Authority (AFSSAPS) told AstraZeneca that it will require more information before the drug can

The H5N1 strain is a new strain of influenza virus that humans have little or no resistance to and has resulted in high rates of illness and death.

Seattle Genetics is currently conducting phase I clinical trials of SGN-40, an anti-CD40 antibody, in multiple myeloma and non-Hodgkin’s lymphoma. The company plans to initiate an additional phase

Under the terms of the transaction, Ortho-McNeil will obtain a one-year exclusive option to selected adenosine receptor antagonists discovered by Adenosine Therapeutics. In connection with this, Johnson &

Paclitaxel, marketed as Taxol by Bristol-Myers Squibb, is a first-line treatment for recurrent head and neck squamous cell carcinoma (HNSCC). Panzem (2-methoxyestradiol or 2ME2), EntreMed’s lead drug candidate,